Want to see SG:P8A full AI Analyst Report?
P8A Stock Chart & Stats
S$0.15
S$0.03(25.00%)
At close: 4:00 PM EDT
S$0.15
S$0.03(25.00%)
Day’s Range― - ―
52-Week RangeS$0.11 - S$0.27
Previous CloseN/A
Volume9.10K
Average Volume (3M)14.19K
Market Cap
S$27.57M
Enterprise ValueS$22.62M
Total Cash (Recent Filing)S$45.33M
Total Debt (Recent Filing)S$4.39M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding267,525,360
10 Day Avg. Volume3,230
30 Day Avg. Volume14,193
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.32
Price to Sales (P/S)0.86
P/FCF Ratio-45.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt provides durable financial flexibility to fund operations, maintain storage facilities, or raise capital without heavy interest burdens. This cushion reduces insolvency risk, supports multi-year customer commitments, and allows opportunistic investment or M&A over the next 2–6 months.
High Gross MarginsA gross margin near 57% indicates structural pricing power and efficient lab processing, providing a lasting buffer against higher fixed costs. If SG&A is controlled, these margins support a path back to profitability as volumes recover, making core unit economics resilient over months.
Modest Revenue Growth And Improving FCF TrendModest TTM revenue growth alongside positive free cash flow growth versus the prior year suggests initial operational stabilization. Given recurring storage fees and distribution partnerships, this trend can be a durable foundation for continued recovery and reduced dependence on external funding over the medium term.
Bears Say
Large Operating And Net LossesSubstantial operating and net losses indicate structural cost or demand issues that erode capital and hinder reinvestment. Persistent negative margins can force cost cuts or external financing, weakening long-term competitiveness and risking service quality for storage and processing operations.
Negative Cash GenerationNegative operating and free cash flow undermine the company's ability to self-fund operations and capital needs. Over a multi-month horizon this raises execution risk, increases reliance on external financing, and could limit marketing, hospital partnerships, or lab investments necessary to grow recurring revenue.
Erosion From Prior Profitability; Negative ROEA reversal from prior profitable years to negative ROE signals a structural deterioration in returns and/or competitive position. This raises questions about management execution and long-term customer demand, potentially limiting reinvestment capacity and making recovery harder without strategic changes.
Cordlife Group News
P8A FAQ
What was Cordlife Group Limited’s price range in the past 12 months?
Cordlife Group Limited lowest share price was S$0.10 and its highest was S$0.27 in the past 12 months.
What is Cordlife Group Limited’s market cap?
Cordlife Group Limited’s market cap is S$27.57M.
When is Cordlife Group Limited’s upcoming earnings report date?
Cordlife Group Limited’s upcoming earnings report date is Aug 07, 2026 which is in 8 days.
How were Cordlife Group Limited’s earnings last quarter?
Cordlife Group Limited released its earnings results on May 13, 2026. The company reported -S$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.007.
Is Cordlife Group Limited overvalued?
According to Wall Street analysts Cordlife Group Limited’s price is currently Overvalued.
Does Cordlife Group Limited pay dividends?
Cordlife Group Limited pays a Annually dividend of S$0.009 which represents an annual dividend yield of N/A. See more information on Cordlife Group Limited dividends here
What is Cordlife Group Limited’s EPS estimate?
Cordlife Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cordlife Group Limited have?
Cordlife Group Limited has 267,525,360 shares outstanding.
What happened to Cordlife Group Limited’s price movement after its last earnings report?
Cordlife Group Limited reported an EPS of -S$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cordlife Group Limited?
Currently, no hedge funds are holding shares in SG:P8A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cordlife Group Limited
Established in Singapore in 2001, Cordlife Group Limited functions as an investment holding company, delivering cord blood banking solutions across a global footprint that includes Singapore, Hong Kong, India, Malaysia, and the Philippines. Its operations are structured into two distinct divisions: Banking and Diagnostics. The Banking division is responsible for the collection, processing, storage, and analysis of vital biological samples such as cord blood, cord lining, and various tissue samples. Meanwhile, the Diagnostics division furnishes an array of diagnostic tests, encompassing genetic and metabolic screenings for newborns, pediatric vision and hearing assessments, allergen testing for children, and genetic evaluations for talent identification. Beyond these core services, Cordlife also engages in corneal lenticule banking, gut microbiome storage, and offers lifestyle-focused genetic screening for adults. The company further provides "Moms Up," a mobile application designed to supply parenting information and resources pertinent to health, wellness, and lifestyle needs. Completing its diverse portfolio, Cordlife offers medical laboratory services, marketing support, property investment, alongside specialized consulting and research and development in the medical and pharmaceutical sectors.
Technical Analysis
Raffles Medical Group
―
Thomson Medical Group Ltd.
―
ISEC Healthcare Ltd
―
OUE Lippo Healthcare Limited
―
Bangkok Dusit Medical Services Public Co Ltd Shs UnSp Singapore Depositary Receipt Repr 2/1 Sh
―